Articles related to THROMBOCYTOPENIA

In a recent study, 95% of ITP patients treated with the novel anti-CD38 monoclonal antibody, CM313, achieved two consecutive platelet counts of at least 50×10^9 per liter within just eight weeks, highlighting the therapy’s efficacy and rapid action.

In the recent phase 3 trial, recombinant ADAMTS13 demonstrated a profound capability to maintain ADAMTS13 activity at approximately 100% of normal levels, highlighting its potential to substantially reduce thrombotic complications in patients with congenital TTP.

In a striking case, a patient with sudden oral hemorrhagic bullae and extremity purpura was diagnosed with immune thrombocytopenia, highlighting the condition’s potential to present atypically and the importance of a comprehensive diagnostic approach.